117 results
PRE 14A
SYRS
Syros Pharmaceuticals Inc.
12 Apr 24
Preliminary proxy
4:30pm
amendments to, or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature … , subject to ratification by the committee at its next meeting. Any related person transactions that are ongoing in nature will be reviewed annually
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
8 Jan 24
Regulation FD Disclosure
7:06am
. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions
424B5
4588f3wd
19 Dec 23
Prospectus supplement for primary offering
4:53pm
8-K
EX-99.1
94w46m puk6pk1pv
6 Dec 23
Regulation FD Disclosure
7:05am
8-K
nrwv2yw7t
2 Oct 23
Cost Associated with Exit or Disposal Activities
8:49am
8-K
kvzpl
21 Jul 23
Termination of a Material Definitive Agreement
4:36pm
8-K
EX-99.1
5g39et
25 May 23
Regulation FD Disclosure
5:10pm
8-K
EX-99.1
s9u692gml7a1490 n58
12 Dec 22
Regulation FD Disclosure
7:48am